Vilarrasa, EvaNicolau, JoanaCueva, Pablo de laGoday Arno, AlbertoGallardo Hernández, FernandoMartorell, AntonioCarrascosa Carrillo, José Manuel2024-04-242024-04-242024Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024 Jan;115(1):T56-T65. DOI: 10.1016/j.ad.2023.10.0190001-7310http://hdl.handle.net/10230/59888Psoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors. These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat, which until recently was the only drug approved for treating obesity in the European Union. Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce, the promising results reported suggest they may offer a useful tool for managing obesity.application/pdfeng© 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.ad.2023.10.019PsoriasisHidradenitis suppurativaObesityGlucagon-like peptide-1 (GLP-1) agonistsLiraglutideSemaglutideinfo:eu-repo/semantics/openAccess